Latham & Watkins Advises Coherus Oncology on Public Offering of Common Stock

Coherus Oncology, Inc. (NASDAQ: CHRS), a commercial‑stage oncology company, has announced the pricing of an underwritten public offering of 28,600,000 shares of its common stock at a public offering price of US$1.75 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by the company. The gross proceeds to Coherus from the offering are expected to be approximately US$50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The company has granted the underwriters a 30‑day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents Coherus in the offering with a corporate team led by Bay Area partner Benjamin Potter and Orange County partner Drew Capurro, with associates Kennedy Holmes, Ivana Valdez, and Skyler Ligon. Advice was also provided on tax matters by Bay Area partner Grace Lee, with associate Gregory Conyers.